Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | DLL4 |
Clinical data | |
Other names | REGN421 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG |
|
Enoticumab (REGN421, INN) is a human monoclonal antibody that binds to DLL4. It acts as an immunomodulator.[1][2][3][4][5]
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems | |||||||||
---|---|---|---|---|---|---|---|---|---|
Bone |
| ||||||||
Musculoskeletal |
| ||||||||
Circulatory |
| ||||||||
Neurologic |
| ||||||||
Angiogenesis inhibitor |
| ||||||||
Growth factor |
| ||||||||
|